Association between oncogenic RAS mutation and radiologic-pathologic findings in patients with primary rectal cancer

Abstract

Background: To evaluate the association between various radiologic-pathologic findings and oncogenic Kirsten-ras (KRAS) mutation in patients with primary rectal cancer. Methods: Seventy-five patients with primary rectal cancer who had undergone rectal magnetic resonance imaging (MRI) were included. The rectal MRI consisted of T2-weighted images in three planes, pre-and postcontrast-enhanced T1-weighted images, and axial diffusion-weighted images (b factors, 0, 1,000 s/mm 2). Two radiologists reviewed the MRI scans and measured the axial and longitudinal tumor lengths (LTLs), apparent diffusion coefficient (ADC), and relative contrast enhancement [signal intensity (SI) difference of tumor on pre-and post-contrast T1WI/SI of tumor on pre-contrast T1WI]. The associations among the qualitative data (tumor stage, node stage, lymphatic invasion, venous invasion, and perineural invasion), quantitative data (tumor length, ADC, relative contrast enhancement) and KRAS mutations were statistically analyzed by Fisher's exact test for the qualitative data and by the Mann-Whitney U test for the quantitative data. An area under receiver operating characteristic curve (AUC) was considered as the diagnostic performance for the prediction of KRAS mutation. Molecular-biologic results served as the reference standard. Results: The ratio of axial to LTL in the KRAS-mutant group (n=41) was higher than that in the wild-type group (n=34) (0.29±0.15; 0.22±0.08, P=0.0117). The AUC was 0.640 (95% CI, 0.520 to 0.747, P=0.0292) with an estimated maximum accuracy of 64%. The mean ADC of the mutant group was not significantly different from that of the wild-type group [(0.95±0.17)×10 −3 mm 2 /s; (0.96±0.17)×10 −3 mm 2 /s, P=0.6505]. The relative contrast enhancement showed no significant difference between the two groups (1.66±0.93, 1.35±0.84, P=0.1581). The other qualitative findings also did not show any significant difference (P>0.05). Conclusions: The ratio of axial to LTL showed a significant difference according to KRAS mutation in patients with primary rectal cancer. However, it showed a low accuracy of 64% for prediction of KRAS mutation.

Radiogenomics in Colorectal Cancer

“…Shin et al found that tumors with KRAS mutations exhibited a longer axial length, as well as a larger ratio of the axial to the longitudinal dimensions on pretreatment rectal MRI [ 72 ]. With an accuracy of 0.640 (95% CI, 0.520 to 0.747, p = 0.0292), the study Jo et al confirmed these findings [ 73 ]. Xu et al reported that lower Max-ADC, Mean-ADC, pure diffusion, and higher pseudo-diffusion coefficient values were demonstrated in the KRAS mutant group [ 74 ].…”

Diffusion-Weighted MRI and Diffusion Kurtosis Imaging to Detect RAS Mutation in Colorectal Liver Metastasis

“…KRAS mutation is associated with morphologic tumor growth patterns. Moreover, increased cell growth activity induced by activated KRAS mutation seems to be essential for polypoid growth in CRC [ 14 ]. Then, the Diffusion-Weighted imaging (DWI) that offers functional quantitative information on the tissue’s microstructure by means of the water proton mobility differences and cellular density evaluation [ 15 , 16 ] can be used in the detection of RAS mutation.…”

Pretreatment Apparent Diffusion Coefficient Cannot Predict Histopathological Features and Response to Neoadjuvant Radiochemotherapy in Rectal Cancer: A Meta-Analysis

“…Three studies (274 patients) analyzed associations between ADC values and KRAS status in RC [19,32,47]. Mutated RC (n = 124, 45.3%) had the calculated mean ADC value (×10 −3 mm 2 /s) of 1.12, 95% CI (0.93, 1.30) (Fig.…”